Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
|Videos|January 9, 2015
Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML
Author(s)Bayard L. Powell, MD
Advertisement
Bayard L. Powell, MD, Section Chief of Hematology and Oncology and Director of Leukemia Services at
Wake Forest University Baptist Medical Center, discusses using the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).
I
look
Powell.
The results of the recent phase study promising. The combination has been effective, with 54% of patients showing a response and no increased toxicity occurring from the addition of CPI-613. The combination was particularly beneficial for patients over 60 and patients with poor risk cytogenetics, says
Advertisement
Related to this article
The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
3
Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)
4
Data Point to Pirtobrutinib-Based Regimens as a New SOC Option for R/R CLL
5